Madrigal Pharmaceuticals Inc
MDGLHealthcare|Biotechnology|USA
$536.70
-23.77 (-4.24%)
Tangible Book
$23.27
Ownership Breakdown
—
Institutional
—
Insider
—
Float
—
Shares Outstanding
Insider Trades (103)
| Insider | Position | Date | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Soergel David | Chief Medical Officer | 2026-06-01 | SELL | 1,042 | $495.74 | $516.6K |
| Levy Richard S | Director | 2026-05-22 | SELL | 5,682 | $515.44 | $2928.7K |
| Soergel David | Chief Medical Officer | 2026-05-18 | SELL | 844 | $515.9 | $435.4K |
| Huntsman Carole | Chief Commercial Officer | 2026-03-06 | SELL | 419 | $431.94 | $181K |
| Dier Mardi | EVP and CFO | 2026-03-06 | SELL | 1,982 | $430.87 | $854K |
| Taub Rebecca | Director | 2026-03-06 | SELL | 491 | $431.94 | $212.1K |
| Kelley Shannon T | General Counsel | 2026-03-06 | SELL | 360 | $431.94 | $155.5K |
| Sibold William John | President and CEO | 2026-03-06 | SELL | 1,663 | $431.94 | $718.3K |
| Dier Mardi | EVP and CFO | 2026-03-02 | SELL | 1,183 | $427.21 | $505.4K |
| Huntsman Carole | Chief Commercial Officer | 2026-01-26 | SELL | 910 | $493.78 | $449.3K |
| Sibold William John | President and CEO | 2026-01-26 | SELL | 1,577 | $492.42 | $776.5K |
| Taub Rebecca | Director | 2026-01-26 | SELL | 647 | $492.42 | $318.6K |
| Kelley Shannon T | General Counsel | 2026-01-20 | SELL | 692 | $497.36 | $344.2K |
| Taub Rebecca | Director | 2026-01-20 | SELL | 2,238 | $490.77 | $1098.3K |
| Taub Rebecca | Director | 2026-01-09 | SELL | 18,410 | $522.4 | $9617.4K |
| FRIEDMAN PAUL A | Director | 2026-01-09 | SELL | 280 | $551.24 | $154.3K |
| FRIEDMAN PAUL A | Director | 2026-01-09 | SELL | 24,520 | $522.39 | $12809K |
| Taub Rebecca | Director | 2026-01-09 | SELL | 240 | $550.33 | $132.1K |
| FRIEDMAN PAUL A | Director | 2025-12-10 | SELL | 24,800 | $552.18 | $13694.1K |
| Taub Rebecca | Director | 2025-12-10 | SELL | 18,650 | $552.15 | $10297.6K |
| Sibold William John | President and CEO | 2025-12-04 | SELL | 2,400 | $575.34 | $1380.8K |
| Dier Mardi | EVP and CFO | 2025-12-02 | SELL | 4,173 | $578.34 | $2413.4K |
| Huntsman Carole | Chief Commercial Officer | 2025-11-21 | SELL | 1,958 | $553.11 | $1083K |
| Levy Richard S | Director | 2025-11-13 | SELL | 8,500 | $520.96 | $4428.2K |
| BATE KENNETH | Director | 2025-11-05 | SELL | 16,575 | $484.3 | $8027.3K |
| Sibold William John | President and CEO | 2025-09-09 | SELL | 7,279 | $445.63 | $3243.7K |
| Sibold William John | President and CEO | 2025-08-21 | SELL | 7,616 | $400.18 | $3047.8K |
| BAKER BROS. ADVISORS LP | Director | 2025-08-20 | BUY | 97,065 | $380.58 | $36941K |
| Kelley Shannon T | General Counsel | 2025-08-18 | SELL | 1,304 | $367.81 | $479.6K |
| BAKER BROS. ADVISORS LP | Director | 2025-08-18 | BUY | 68,618 | $364.04 | $24979.7K |
| BATE KENNETH | Director | 2025-08-15 | SELL | 10,000 | $365.2 | $3652K |
| FRIEDMAN PAUL A | Director | 2025-08-13 | SELL | 129,172 | $370.24 | $47824.6K |
| FRIEDMAN PAUL A | Director | 2025-08-12 | SELL | 46,808 | $355.31 | $16631.4K |
| Taub Rebecca | Director | 2025-08-12 | SELL | 46,463 | $355.32 | $16509.2K |
| Taub Rebecca | Director | 2025-07-18 | SELL | 1,000 | $350.01 | $350K |
| FRIEDMAN PAUL A | Director | 2025-07-18 | SELL | 1,400 | $350.03 | $490K |
| FRIEDMAN PAUL A | Director | 2025-07-17 | SELL | 28,876 | $353.19 | $10198.7K |
| Taub Rebecca | Director | 2025-07-17 | SELL | 29,101 | $353.19 | $10278.2K |
| CRAVES FRED B | Director | 2025-03-13 | SELL | 15,470 | $328.54 | $5082.5K |
| Dier Mardi | SVP and CFO | 2025-03-10 | SELL | 258 | $323.04 | $83.3K |
| Waltermire Robert E. | Senior VP, Chief Pharma Dev. | 2025-03-05 | SELL | 14,113 | $341.32 | $4817K |
| Huntsman Carole | Chief Commercial Officer | 2025-03-03 | SELL | 1,834 | $325.98 | $597.8K |
| Kelley Shannon T | General Counsel | 2025-03-03 | SELL | 415 | $335 | $139K |
| Dier Mardi | SVP and CFO | 2025-03-03 | SELL | 1,961 | $324.96 | $637.2K |
| Waltermire Robert E. | Senior VP, Chief Pharma Dev. | 2025-02-28 | SELL | 1,227 | $341.07 | $418.5K |
| BATE KENNETH | Director | 2025-02-27 | SELL | 20,000 | $356.44 | $7128.8K |
| Daly James M | Director | 2025-02-27 | SELL | 15,470 | $347.45 | $5375.1K |
| Huntsman Carole | Chief Commercial Officer | 2025-01-24 | SELL | 347 | $335.24 | $116.3K |
| Sibold William John | President and CEO | 2025-01-24 | SELL | 1,584 | $335.24 | $531K |
| Taub Rebecca | Pres., R&D, and CMO | 2025-01-24 | SELL | 648 | $335.24 | $217.2K |
| Waltermire Robert E. | Senior VP, Chief Pharma Dev. | 2025-01-24 | SELL | 103 | $335.24 | $34.5K |
| Kelley Shannon T | General Counsel | 2025-01-17 | SELL | 277 | $273.41 | $75.7K |
| Waltermire Robert E. | Senior VP, Chief Pharma Dev. | 2025-01-17 | SELL | 442 | $273.41 | $120.8K |
| Taub Rebecca | Pres., R&D, and CMO | 2025-01-17 | SELL | 1,689 | $273.41 | $461.8K |
| CRAVES FRED B | Director | 2024-12-03 | SELL | 3,600 | $315.31 | $1135.1K |
| CRAVES FRED B | Director | 2024-11-25 | SELL | 3,400 | $350.3 | $1191K |
| Huntsman Carole | Chief Commercial Officer | 2024-11-21 | SELL | 688 | $316.92 | $218K |
| Levy Richard S | Director | 2024-11-07 | SELL | 5,000 | $350 | $1750K |
| Levy Richard S | Director | 2024-11-01 | SELL | 5,000 | $300.94 | $1504.7K |
| Sibold William John | President and CEO | 2024-09-09 | SELL | 6,363 | $243.83 | $1551.5K |
| Waltermire Robert E. | Senior VP, Chief Pharma Dev. | 2024-06-14 | SELL | 1,900 | $280 | $532K |
| Waltermire Robert E. | Senior VP, Chief Pharma Dev. | 2024-06-12 | SELL | 2,000 | $285 | $570K |
| Waltermire Robert E. | Senior VP, Chief Pharma Dev. | 2024-05-21 | SELL | 1,036 | $231.34 | $239.7K |
| CRAVES FRED B | Director | 2024-05-14 | SELL | 22,489 | $212.88 | $4787.5K |
| Taub Rebecca | Pres., R&D, and CMO | 2024-04-08 | SELL | 2,676 | $245.99 | $658.3K |
| FRIEDMAN PAUL A | Director | 2024-04-08 | SELL | 26,270 | $246.19 | $6467.4K |
| Taub Rebecca | Pres., R&D, and CMO | 2024-04-05 | SELL | 73,888 | $243.92 | $18022.8K |
| FRIEDMAN PAUL A | Director | 2024-04-05 | SELL | 73,730 | $243.93 | $17985K |
| BATE KENNETH | Director | 2024-04-02 | SELL | 32,489 | $252.85 | $8214.8K |
| Daly James M | Director | 2024-04-02 | SELL | 32,489 | $252.97 | $8218.7K |
| Levy Richard S | Director | 2024-04-01 | SELL | 11,000 | $257.48 | $2832.3K |
| Waltermire Robert E. | Senior VP, Chief Pharma Dev. | 2023-12-15 | SELL | 4,000 | $235.5 | $942K |
| BAKER BROS. ADVISORS LP | Director | 2023-12-14 | BUY | 101,792 | $221.2 | $22516.4K |
| Waltermire Robert E. | Senior VP, Chief Pharma Dev. | 2023-12-13 | SELL | 3,800 | $222.82 | $846.7K |
| BAKER BROS. ADVISORS LP | Director | 2023-12-12 | BUY | 34,578 | $218.31 | $7548.7K |
| Lynch Brian Joseph | SVP and General Counsel | 2023-12-05 | SELL | 2,800 | $221.89 | $621.3K |
| Lynch Brian Joseph | SVP and General Counsel | 2023-11-30 | SELL | 7,000 | $201.5 | $1410.5K |
| BAKER BROS. ADVISORS LP | Director | 2023-11-21 | BUY | 64,350 | $188.47 | $12128K |
| BAKER BROS. ADVISORS LP | Director | 2023-11-20 | BUY | 67,079 | $178.11 | $11947.4K |
| BAKER BROS. ADVISORS LP | Director | 2023-11-15 | BUY | 49,387 | $158.13 | $7809.6K |
| BAKER BROS. ADVISORS LP | Director | 2023-11-14 | BUY | 107,499 | $146.99 | $15801.3K |
| Levy Richard S | Director | 2023-01-17 | SELL | 22,489 | $293.15 | $6592.7K |
| Lynch Brian Joseph | SVP and General Counsel | 2023-01-03 | SELL | 13,000 | $282.92 | $3678K |
| Lynch Brian Joseph | SVP and General Counsel | 2022-12-23 | SELL | 7,000 | $274.18 | $1919.3K |
| Sukhija Remy | Chief Commercial Officer | 2022-12-23 | SELL | 30,000 | $274.14 | $8224.2K |
| BAY CITY CAPITAL LLC | 10% Owner | 2020-08-19 | SELL | 30,000 | $109.74 | $3292.2K |
| CRAVES FRED B | Director, 10% Owner | 2020-08-19 | SELL | 30,000 | $109.74 | $3292.2K |
| BAY CITY CAPITAL LLC | 10% Owner | 2019-12-13 | SELL | 1,200,000 | $105.47 | $126564K |
| CRAVES FRED B | Director, 10% Owner | 2019-12-13 | SELL | 1,200,000 | $105.47 | $126564K |
| MILLIGAN DAVID V | Director | 2018-11-21 | SELL | 20,000 | $112.54 | $2250.8K |
| FRIEDMAN PAUL A | CEO | 2018-11-20 | BUY | 4,000 | $117.88 | $471.5K |
| MILLIGAN DAVID V | Director | 2018-11-19 | SELL | 10,000 | $131.6 | $1316K |
| FRIEDMAN PAUL A | CEO | 2018-11-19 | BUY | 4,000 | $124 | $496K |
| CRAVES FRED B | Director, 10% Owner | 2018-11-19 | BUY | 2,000 | $124.69 | $249.4K |
| Schneebaum Marc R | CFO | 2018-06-11 | SELL | 10,099 | $287.46 | $2903.1K |
| CRAVES FRED B | Director, 10% Owner | 2018-06-11 | SELL | 5,908 | $287.46 | $1698.3K |
| CRAVES FRED B | Director, 10% Owner | 2018-06-11 | SELL | 280,000 | $287.46 | $80488.8K |
| FRIEDMAN PAUL A | CEO | 2018-06-11 | SELL | 73,526 | $287.46 | $21135.8K |
| Taub Rebecca | Chief Medical Officer, EVP R&D | 2018-06-11 | SELL | 73,526 | $287.46 | $21135.8K |
| BAY CITY CAPITAL LLC | Director, 10% Owner | 2018-06-11 | SELL | 280,000 | $287.46 | $80488.8K |
| Levy Richard S | Director | 2017-08-23 | BUY | 2,000 | $16.12 | $32.2K |
| Levy Richard S | Director | 2017-08-22 | BUY | 3,550 | $16.12 | $57.2K |
| Levy Richard S | Director | 2017-08-21 | BUY | 3,550 | $15.88 | $56.4K |
Congress & Senate Trades
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Guru Activity
1 gurus tracked